New insulin glargine 300 unitszm L21 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin Glargine 100 UnitszmL21

Diabetes Care

Volumn 38, Issue 4, 2015, Pages 637-643

  Becker, Reinhard H A ^a   Dahmen, Raphael ^a   Bergmann, Karin ^a   Lehmann, Anne ^a   Jax, Thomas ^b   Heise, Tim ^b  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b Profil   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; BLOOD; DIABETES MELLITUS, TYPE 1; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84929019522     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0006     Document Type: Article

References (21)

1. Bolli GB, Andreoli AM, Lucidi P. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 2011;13 (Suppl. 1):S43-S52.
2. Arnolds S, Kuglin B, Kapitza C, Heise T. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract 2010;64: 1415-1424.
3. Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther 2011;13(Suppl. 1):S103-S108.
4. Steiner DF. Adventures with insulin in the islets of Langerhans. J Biol Chem 2011;286: 17399-17421.
5. Kuerzel GU, Shukla U, Scholtz HE, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003;19:34-40.
6. Markussen J, Diers I, Hougaard P, et al. Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. Protein Eng 1988;2:157-166.
7. Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care 2012;35:2626-2630.
8. Krayenbuhl C, Rosenberg T. Crystalline protamine insulin. Rep Steno Mem Hosp Nord Insulin Lab 1946;1:60-73.
9. Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther 2011;13 (Suppl. 1):S5-S14.
10. Gualandi-Signorini AM, Giorgi G. Insulin formulationsda review. Eur RevMed Pharmacol Sci 2001;5:73-83.
11. Barlocco D. Insulin detemir. Novo Nordisk. Curr Opin Investig Drugs 2003;4:449-454.
12. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times aweek versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase 2 trial. Lancet 2011;377:924-931.
13. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of oncedaily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147.
14. Tillner J, Bergmann K, Teichert L, et al. Euglycemic clamp profile of new insulin glargine U300 formulation in patients with type 1 diabetes (T1DM) is different from glargine U100 (Abstract). Diabetes 2013;62(Suppl. 1):A234.
15. Becker RH, Hahn AD, Boderke P, et al. Longacting formulations of insulins. European patent application 11166415.7. 17 May 2011.
16. Steinstraesser A, Schmidt R, Bergmann K, Dahmen R, Becker RH. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 2014;16:873-876.
17. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: A report from the AmericanDiabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249.
18. Riddle MC, Bolli GB, Ziemen M, et al.; EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014;37:2755-2762.
19. Yki-Jarvinen H, Bergenstal R, ZiemenM, et al.; EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014;37:3235-3243.
20. Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014;16:344-350.
21. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14: 944-950.